RNA metabolism-focused Gotham Therapeutics launches with $54M Series A round
The company, focused on epitranscriptomics, launched with backing from Versant Ventures, Forbion, GSK's venture capital arm, Celgene and others.
Accent Therapeutics launches with $40 million Series A round
Company will pursue RNA-modifying protein targets to discover and develop new treatments in oncology.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.